PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2024-09-19

Date Title Company
19-Sep-2024 Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 AccessWire
19-Sep-2024 Theralase(R) Extends Warrants AccessWire
19-Sep-2024 Tenon Medical Announces Issuance of Three Notices of Allowance for Patent Applications from the USPTO AccessWire
19-Sep-2024 Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion AccessWire
19-Sep-2024 Pioneer Group and Novo Nordisk team up on Golden Ticket Programme for cardiometabolic health innovations Pioneer Group
19-Sep-2024 Renovos Biologics strengthens its Board’s US expertise with appointment of Lisa Ferrara, Ph.D., as a Non-Executive Director Renovos Biologics
19-Sep-2024 Bayer submits application to MHRA for elinzanetant to treat moderate to severe vasomotor systems associated with menopause in women Bayer
19-Sep-2024 Biocomposites acquires remaining shares in manufacturers of SYNICEMTM and Subiton products Biocomposites
19-Sep-2024 San Francisco Medical Waste Disposal Firm Mitigates Increase in Needlestick Injuries With Key Resource AccessWire
19-Sep-2024 New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment TG THERAPEUTICS
19-Sep-2024 Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease Tiziana Life Sciences
19-Sep-2024 Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor STALICLA SA
19-Sep-2024 Aston Institute for Membrane Excellence celebrates official launch with multidisciplinary event Aston University
19-Sep-2024 Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer Autolus Therapeutics plc
19-Sep-2024 New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment TG THERAPEUTICS
19-Sep-2024 Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems Biognosys
19-Sep-2024 Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024 Ketabon GmbH
19-Sep-2024 ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape Wilson Wolf Manufacturing
19-Sep-2024 OEAW AND BOEHRINGER INGELHEIM FOUNDATION ESTABLISH NEW INSTITUTE FOR BIOMEDICAL ARTI-FICIAL INTELLIGENCE IN VIENNA Boehringer Ingelheim
19-Sep-2024 Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis AstraZeneca